Medical Oncologist
Kidney cancer treatment
Targeted Therapy for — Kidney Cancer
Kidney cancer responds to targeted drugs and immunotherapy, not chemotherapy. Which treatment your oncologist recommends depends on the exact subtype of your cancer and a risk score calculated at diagnosis — both of which take only days to establish.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Subtype decides the approach — Clear cell RCC and non-clear cell subtypes are treated differently, so your biopsy report is the starting point for every treatment decision.
- Oral tablets, not only infusions — Most targeted drugs for kidney cancer are taken as daily tablets at home. Some regimens add an intravenous immunotherapy drug given at a day care centre.
- IMDC risk score guides the choice — A six-factor clinical score places you in favourable, intermediate, or poor risk. This directly shapes which drug or combination is offered first.
- Gene panel testing is rarely needed first — Unlike some cancers, most clear cell RCC treatment decisions do not require a mutation panel before starting.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Most kidney cancers respond to targeted drugs, not chemotherapy. The right drug depends on your tumour subtype — most often clear cell — and your IMDC risk score, both established at diagnosis. NCCN and ESMO guidance now places combinations of targeted therapy and immunotherapy as the standard first approach for advanced clear cell kidney cancer.
What testing is done before targeted therapy starts?
The first step is confirming your kidney cancer subtype from your biopsy report. Clear cell RCC, the most common type, is treated on a different evidence base from papillary, chromophobe, collecting duct, and other subtypes. This distinction matters before any treatment decision is made.
Your oncologist will also calculate your IMDC risk score using clinical factors from your blood tests and performance assessment at diagnosis. This score — favourable, intermediate, or poor risk — is the main guide to which drug or combination is recommended first.
Mutation panel testing is not required before starting most clear cell RCC treatments. It becomes more relevant if your cancer does not respond, if a clinical trial is being considered, or if a hereditary kidney cancer syndrome is suspected.
What do these kidney cancer terms mean?
- Clear cell RCC
- The most common kidney cancer subtype, named for how the cells appear under the microscope. Most targeted therapy trials have focused on clear cell patients, so this is where the evidence base is strongest.
- Non-clear cell RCC
- A group of less common subtypes — papillary, chromophobe, collecting duct, and others. The same drug classes are often used, but with less trial evidence, and clinical trial participation is particularly important here.
- VEGF pathway
- A signalling route kidney tumours use to grow new blood vessels and sustain themselves. Most targeted drugs for kidney cancer work by blocking this pathway, cutting off the tumour's blood supply.
- mTOR pathway
- A second growth pathway active in some kidney cancers. Drugs that block mTOR are used mainly when VEGF-targeted drugs have stopped working, or in certain non-clear cell subtypes.
- IMDC risk score
- A clinical tool that places you in favourable, intermediate, or poor risk based on six factors at diagnosis. It is the main guide to which first-line treatment your oncologist recommends.
- TKI (tyrosine kinase inhibitor)
- The main class of targeted drugs used in kidney cancer. Most are taken as daily oral tablets at home. They block multiple signals that kidney tumour cells use to grow and spread.
- VHL gene
- A gene frequently altered in clear cell RCC. When it stops functioning, it triggers the VEGF pathway. This is why VEGF-blocking TKIs work in most clear cell kidney cancers.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Which targeted drugs are used for kidney cancer?
TKIs are the main targeted drug class for kidney cancer. They are oral tablets that block VEGF signalling. Several TKIs are available, and your oncologist selects from them based on your IMDC risk group, your other medical conditions, and whether a combination with immunotherapy is planned.
NCCN and ESMO guidance now recommends combining a TKI with a PD-1 or PD-L1 immunotherapy drug as the standard first approach for most patients with advanced clear cell RCC. The immunotherapy component is given as an intravenous infusion every few weeks; the TKI is taken as a daily tablet at home.
If your disease progresses after first-line treatment, a different TKI or an mTOR-blocking drug may be offered. For non-clear cell subtypes, your oncologist follows adapted guidelines, and clinical trial participation is an important option where the evidence base is still developing.
Did you know?
Kidney cancer is one of the few solid tumours that proved largely resistant to standard chemotherapy. The shift to VEGF-targeted drugs transformed the treatment outlook for advanced RCC — and the later addition of immunotherapy combinations improved it further.
Both changes were built on understanding the VHL–VEGF biology that underlies most clear cell kidney cancers.
Source: ESMO Clinical Practice Guidelines — Renal Cell Carcinoma
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is chemotherapy used for kidney cancer?
Chemotherapy is not a standard treatment for kidney cancer. Kidney cancer cells are largely resistant to most chemotherapy agents, which is why targeted therapy and immunotherapy have become the main systemic options. NCCN and ESMO guidance does not include chemotherapy in first- or second-line treatment algorithms for RCC, and your oncologist will not typically recommend it unless very specific and unusual circumstances apply.
How long do I take the targeted therapy tablets?
Targeted therapy for kidney cancer is taken continuously, not in fixed cycles the way chemotherapy is. You stay on it until the disease progresses, side effects become unmanageable, or your oncologist has another clinical reason to stop. This means regular monitoring — blood tests and scans throughout treatment — to check your response and catch side effects early. If you need to stop one drug, switching to another option is usually possible.
What are the common side effects of TKIs for kidney cancer?
Common side effects include high blood pressure, fatigue, hand-foot skin reaction (redness and soreness on the palms and soles), diarrhoea, and changes in thyroid function. High blood pressure is particularly common and is usually managed with blood pressure medication rather than stopping the TKI. Your team will check your blood pressure at every visit and monitor your thyroid with blood tests. Reporting new symptoms early makes them easier to manage.
Will I need to come in for infusions, or is it all tablets?
Most TKIs are oral tablets taken at home. If your regimen includes an immunotherapy drug — as many standard first-line combinations now do — that component is given as an intravenous infusion at a day care centre, usually every two to four weeks. Your specific schedule depends on which combination your oncologist recommends and your IMDC risk group. At CION, immunotherapy infusions are given as day care, so you do not need to be admitted overnight.
What happens if the first targeted therapy stops working?
If your kidney cancer progresses on first-line treatment, second- and third-line options exist. Your oncologist may switch to a different TKI, move to an mTOR-blocking drug, or recommend a clinical trial. Kidney cancer is one of the solid tumour types where multiple lines of treatment are available, and switching after progression is a planned part of the treatment strategy rather than a last resort.
Does targeted therapy work for non-clear cell kidney cancer?
Non-clear cell subtypes — including papillary, chromophobe, and collecting duct cancers — are underrepresented in the large targeted therapy trials, so the evidence is thinner. Some of the same TKI drug classes are used, guided by expert consensus and smaller studies. ESMO and NCCN guidance specifically recommends clinical trial participation for non-clear cell patients where possible, because the evidence base is still developing. Your oncologist will explain which options apply to your specific subtype.